Arcutis director plans sale of 1,072 shares

Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran plans to sell 1,072 shares of the company’s common stock.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran plans to sell 1,072 shares of the company’s common stock. The shares are to be sold through Merrill Lynch on the NASDAQ, with cash as the form of payment and were acquired via a stock option exercise dated 05/31/2023.

Key Figures

Shares to be sold: 1,072 shares of common stock Aggregate market value: 27912.35 Date of acquisition: 05/31/2023 +1 more

4 metrics

Shares to be sold 1,072 shares of common stock Quantity of Arcutis Biotherapeutics, Inc. shares covered by the Rule 144 notice

Aggregate market value 27912.35 Aggregate market value reported for the 1,072 shares of common stock

Date of acquisition 05/31/2023 Date the securities to be sold were acquired via stock option exercise

Planned sale date or period reference 08/20/2026 Date associated with the securities information and to-be-sold sections

Key Terms

Rule 144, Stock Option Exercise, Aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 05/31/2023 | Stock Option Exercise | Arcutis Biotherapeutics"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate market value financial

"Common | Merrill Lynch ... | 1072 | 27912.35 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ARQT disclose about planned share sales?

It discloses that Terrie Curran plans to sell 1,072 shares of Arcutis Biotherapeutics, Inc. common stock under Rule 144, through Merrill Lynch, with the securities listed on NASDAQ and acquired via a stock option exercise dated 05/31/2023.

How many ARQT shares are planned to be sold under this Form 144?

The notice states that 1,072 shares of Arcutis Biotherapeutics, Inc. common stock are proposed to be sold under Rule 144. These shares were acquired through a stock option exercise on 05/31/2023 and are to be sold for cash.

Who is the selling security holder in the ARQT Form 144 filing?

The selling security holder is Terrie Curran, identified as a Director. The filing covers a proposed sale of 1,072 shares of Arcutis Biotherapeutics, Inc. common stock that were acquired via stock option exercise.

Through which broker will the ARQT shares be sold according to the Form 144?

The filing lists Merrill Lynch, located at 8890 Lyra Drive, as the broker handling the proposed sale of 1,072 shares of Arcutis Biotherapeutics, Inc. common stock. The shares are listed on NASDAQ and the sale is for cash.

How were the ARQT shares to be sold under Form 144 acquired?

The 1,072 shares of Arcutis Biotherapeutics, Inc. common stock covered by this Form 144 were acquired through a stock option exercise dated 05/31/2023, as indicated in the securities-to-be-sold section of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:51 PM Accepted by SEC EDGAR 08/20/2026 - 04:50 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001690298
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Terrie Curran
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1072	27912.35	125691961	08/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1072	08/20/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Terrie Curran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)